Compare NTWK & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTWK | ATRA |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.7M | 38.9M |
| IPO Year | 1997 | 2014 |
| Metric | NTWK | ATRA |
|---|---|---|
| Price | $3.41 | $4.84 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 12.7K | ★ 56.8K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.67 | 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | $73,088,687.00 | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.91 |
| Revenue Growth | ★ 13.40 | N/A |
| 52 Week Low | $2.34 | $3.92 |
| 52 Week High | $5.75 | $19.15 |
| Indicator | NTWK | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 47.21 |
| Support Level | $3.22 | $4.22 |
| Resistance Level | $3.69 | $5.47 |
| Average True Range (ATR) | 0.13 | 0.33 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 39.33 | 33.59 |
NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).